Under the agreement, Moderna receives a license to use Nanexa’s PharmaShell drug delivery platform with its first selected compound and holds options to obtain licenses for up to four additional compounds.

Up to a total of USD 500 million

If Moderna exercises its options for additional compounds following preclinical evaluation, each option would trigger a pre-negotiated license. The overall deal structure includes development and commercial milestone payments to Nanexa of up to a total of USD 500 million, as well as a tiered single-digit royalty on future product sales.

“We are excited to partner with Moderna, a pioneer and leader in the field of mRNA medicines, to explore the potential of our PharmaShell platform and to support the development of improved products for Moderna,” says David Westberg, CEO of Nanexa. “This agreement underscores the versatility of PharmaShell and its potential to address key challenges in the delivery of advanced biologics.”